Coronavirus personalised risk modelsCOVID-19 Datasets Viewer
Clinical Studies
Metadata of the studies included in the viewer.
| Publication reference | URL of Dataset | Clinical Trial ID | Country | Country code | Study design | Total number of subjects | Ethnicity | Existent variables | Exclusion criteria | Inclusion criteria | Demographic | Clinical variables | Laboratory variables | Comorbidities | Drugs | Imaging | Endpoint | Type of data |
|---|
Publication reference | URL of Dataset | Clinical Trial ID | Country | Country code | Study design | Total number of subjects | Ethnicity | Existent variables | Exclusion criteria | Inclusion criteria | Demographic | Clinical variables | Laboratory variables | Comorbidities | Drugs | Imaging | Endpoint | Type of data |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://doi.org/10.1001/jama.2020.10044 | NaN | ChiCTR2000029757 | China | CHN | Longitudinal | 103 | NaN | Demographic|Clinical|Laboratory|Viral load|Comorbidities | NaN | Signed informed consent|Aged at least 18 years|COVID-19 diagnosisbased on polymerase chain reaction (PCR) testing|Posi-tive PCR result within 72 hours prior to randomization|Pneumonia confirmed by chest imaging|Clinical symp-toms meeting the definitions of severe or life-threatening COVID-19|Acceptance of random group assignment|Hospital admission|Willingness to participate in allnecessary research studies and be able to complete the study follow-up|No participation in other clinical trials,such as antiviral trials, during the study period | Age|Sex | Temperature|Respiratory rate|Heart Rate|Systolic blood pressure | White blood cell count|Neutrophil count|Platelet count|C-Reactive protein|Interleukin-6|Prothrombin time|Activated partial thromboplastin time|Thrombin time|Fibrinogen|D-Dimer|Alanine aminotransferase|Aspartate aminotransferase|Urea nitrogen|Serum creatinine | Hypertension|Cardiovascular disease|Cerebrovascular disease|Diabetes|Liver disease|Cancer|Kidney disease | NaN | NaN | Mortality | Structured |
| https://doi.org/10.1001/jama.2020.17022 | NaN | NCT02735707 | Australia|Canada|France|Ireland|the Netherlands|New Zealand|the United Kingdom|and the United States. | GBR,USA | Longitudinal | 614 | White|Asian|Black|Mixed|Other | Demographic|Clinical | NaN | NaN | Age|Sex|BMI | NaN | NaN | NaN | NaN | NaN | NaN | Unstructured |
| https://doi.org/10.1001/jama.2020.4326 | NaN | NaN | USA | USA | Observational | 21 | NaN | Clinical|Laboratory|Comorbidities|Imaging | NaN | NaN | NaN | Temperature | White blood cell count|Absolute lymphocyte count|Hemoglobin|Platelet count|Sodium|Creatinine|Total bilirubin|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Creatinine kinase|Venous lactate|Troponin level|Brain-type natriuretic peptide|Procalcitonin | Asthma|Chronic obstructive pulmonary disease|Congestive heart failure|Diabetes|Rheumatalogic disease|Obstructive sleep apnea|Chronic kidney disease|End stage renal failure|History of solid organ transplantion|Cirrhosis|Immunosuppression | NaN | CT scan | Death|Remains critically ill and requires mechanicalventilation|Survived to transfer out of ICU|Length of follow-up for those who survived or remaincritically ill | NaN |
| https://doi.org/10.1001/jamacardio.2020.1834 | NaN | NaN | USA | USA | Interventional | 90 | NaN | Demographic|Laboratory|Comorbidities|Drugs | NaN | NaN | Age|Sex|BMI | NaN | Serum creatinine|White blood cell count|Absolute lymphocyte count|Maximum temperature on day of treatment initiation|C-Reactive protein|Creatine phosphokinase|D-Dimer|Lactate dehydrogenase|Ferritin | Hypertension|Congestive heart failure|Diabetes|Coronary artery disease|Atrial fibrillation|Chronic obstructive pulmonary disease|Asthma | Hydroxychloroquine|Azithromycin | NaN | NaN | Structured |
| https://doi.org/10.1001/jamaoto.2020.5074 | https://clinicaltrials.gov/show/NCT04407494 | NCT04407494 | France | FRA | Observational | 809 | NaN | Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA (Clinical Olfactory dysfunction Assessment) | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| https://doi.org/10.1002/ejhf.1924 | NaN | NaN | UK | GBR | Interventional | 12000 | Caucasian|Black|Asian|Unknown|Mixed|Other | Demographic|Laboratory|Comorbidities|Drugs | NaN | Admission of symptomatic patients | Age|Sex|BMI | NaN | Systolic blood pressure|Diastolic blood pressure | Hypertension|Diabetes|Heart failure|Ischaemic Heart Disease|Chronic obstructive pulmonary disease|Asthma|Chronic kidney disease|Previous stroke/TIA | ACEi|ARB|Statins|Beta-blocker | NaN | Death|Critical Care|Alive | NaN |
| https://doi.org/10.1002/jmv.25893 | NaN | NaN | China | CHN | Interventional | 184 | NaN | Demographic|Laboratory|Drugs|Imaging | NaN | NaN | Age|Sex | NaN | Alanine aminotransferase|Aspartate aminotransferase|Leukocyte count|Neutrophil count|Lymphocyte count|Erythrocyte sedimentation rate | NaN | Arbidol|Lopinavir/Ritonavir|Interferon-α|Darunavir | CT scan | NaN | Structured |
| https://doi.org/10.1002/joa3.12405 | https://clinicaltrials.gov/show/NCT04395664 | NCT04395664 | Denmark | DNK | Observational | 1000 | NaN | In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Mortality | NaN |
| https://doi.org/10.1007/s00125-020-05180-x | https://clinicaltrials.gov/show/NCT04324736 | NCT04324736 | France | FRA | Observational | 1317 | Europid|Middle East North Africa|African or Caribbean|Asian | Demographic|Laboratory|Comorbidities | NaN | Hospitalisation in a dedicated COVID-19 unit with COVID-19 diagnosis confirmed biologically (by SARS-CoV-2 PCR test) and/or clinical-ly/radiologically (i.e. as ground-glass opacity and/orcrazy paving on chest computed tomography [CT]scan)|Personal history of diabetes or newly diag-nosed diabetes on admission | Age|Sex|BMI | NaN | Positive SARS-CoV-2 PCR|Admission plasma glucose|Plasma creatinine|Estimated glomerular filtration rate|Alanine aminotransferase|Aspartate aminotransferase|Glutamyl transferase|Hemoglobin|White blood cell count|Lymphocyte count|Platelet count|D-Dimer|C-Reactive protein|Lactate dehydrogenase|Fibrinogen|Creatinine phosphokinase | Heart failure|Liver cirrhosis|Cancer|Chronic obstructive pulmonary disease|Obstructive sleep apnea|Organ failure|End stage renal failure | NaN | CT scan | Death|Discharged | NaN |
| https://doi.org/10.1007/s10554-020-02010-4 | https://clinicaltrials.gov/show/NCT04358952 | NCT04358952 | France | FRA | Longitudinal | 50 | NaN | Demographic|Clinical|Laboratory|Comorbidities|Viral load|Electrocardiogram|Inflammatory parameter | NaN | NaN | Age|Sex|BMI | Systolic Arterial pressure|Diastolic Arterial pressure|Heart Rate | High-sensitivity Troponin|NT-proBNP|Creatinine|Leukocyte count|Lymphocyte count|Platelet count|Hemoglobin|C-Reactive protein|Alanine aminotransferase|Aspartate aminotransferase|Estimated glomerular filtration rate | Hypertension|Diabetes|Hypercholesterolemia|Obesity|Cerebrovascular disease|Chronic renal failure|Chronic obstructive pulmonary disease|Sleep disordered breathing | NaN | NaN | NaN | NaN |
Showing 1 to 10 of 143 entries
Geographic location of the studies
- 1:
- 2:
- 3:
- 4:
- 5:
- 8:
- 10:
- 13:
- 17:
- 19:
- 30:
Serology Studies
Metadata of the studies included in the viewer.
| Publication reference | URL of Dataset | Clinical Trial ID | Country | Country code | Study design | Total number of subjects | Ethnicity | Existent variables | Exclusion criteria | Inclusion criteria | Demographic | Clinical variables | Laboratory variables | Comorbidities | Drugs | Imaging | Endpoint | Type of data |
|---|
Publication reference | URL of Dataset | Clinical Trial ID | Country | Country code | Study design | Total number of subjects | Ethnicity | Existent variables | Exclusion criteria | Inclusion criteria | Demographic | Clinical variables | Laboratory variables | Comorbidities | Drugs | Imaging | Endpoint | Type of data |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMID:32306864 | https://pubmed.ncbi.nlm.nih.gov/32306864/ | NaN | China | CHN | Longitudinal | 21.0 | NaN | Laboratory|Demographic | NaN | NaN | Age|Sex | NaN | Anti SARS-CoV-2 IgG|Anti SARS-CoV-2 IgM | NaN | NaN | NaN | NaN | Structured |
| PMID:32337590 | https://academic.oup.com/cid/article/71/16/2255/5825506#supplementary-data | NaN | China | CHN | Longitudinal | 41.0 | NaN | Clinical|Demographic|Laboratory | NaN | NaN | Age|Sex|Epidemiological history | Serum samples | IgG |IgM|Serological responses to SARS-CoV-2| Detection of nucleocapsid (N) protein and spike (S) glycoprotein | NaN | NaN | Chemuluminescent immunoassay | IgG|IgM | Structured |
| PMID:32389784 | https://www.journalofinfection.com/article/S0163-4453(20)30244-9/fulltext | NaN | France | FRA | Longitudinal | 22.0 | NaN | Clinical|Laboratory | NaN | NaN | NaN | Serum samples | IgM|IgG|Antibody detection | NaN | NaN | NaN | IgM|IgG | Structured |
| PMID:32476258 | https://pubmed.ncbi.nlm.nih.gov/32476258/ | NaN | USA | USA | Longitudinal | 9.0 | Black|Latino|Asian|NH/PI|White | Laboratory|Demographic|Clinical | NaN | NaN | Age|Sex|BMI | Temperature | WBC count|Lymphocyte|Platelets|Creatinine|Aspartate aminotransferase|Alanine aminotransferase|Troponin|C-Reactive Protein|Lactate dehydrogenase|Procalcitonin|D-Dimer | Cerebrovascular disease|Continuous renal replacement therapy|Deceased donor renal transplant|Diabetes mellitus|Ground-glass opacities|Hyperlipedimia|Hypertension|Asthma|Dementia|Hypothyroid|Sarcoidosis|Gout|Heart failure with reduced ejection fraction|Upper respiratory symptoms|Rheumatoid arthritis | Hydroxychloroquine|Lopinavir/ritonavir| | CT scan | Discharged ICU|Discharged hospital|Died | Structured |
| PMID:32511324 | https://www.biorxiv.org/content/10.1101/2020.03.24.006544v1 | NaN | USA | USA | Longitudinal | NaN | NaN | Laboratory | NaN | NaN | NaN | NaN | IgG | NaN | NaN | NaN | NaN | Structured |
| PMID:32511499 | https://www.medrxiv.org/content/early/2020/05/14/2020.05.10.20097535.external-links | NaN | USA | USA | Cross-sectional | 180.0 | Asian|Afro American|Non-hispanic Caucasian|Hispanic|Other | Clinical|Demographic|Laboratory | NaN | NaN | Age|Sex|Ethnicity | Serum samples|Plasma samples|Days since symptom onset|Respiratory failure requiring intubation|Duration of disease|Clinical symptoms | IgM|IgG | NaN | NaN | NaN | IgG|IgM | Structured |
| PMID:32638712 | https://pubmed.ncbi.nlm.nih.gov/32638712/ | NaN | UK | GBR | Longitudinal | 74.0 | NaN | Laboratory|Demographic | NaN | NaN | Age|Sex | NaN | IgM|IgA|IgG | NaN | NaN | NaN | Death|Discharged | Structured |
| PMID:32705575 | NaN | NaN | China | CHN | Longitudinal | 88.0 | NaN | Clinical|Demographic|Laboratory | NaN | NaN | Age|Sex | Serum samples| Mild/moderate symptoms|Severe(critical symptoms) | IgG|IgM|Antibody titer | NaN | NaN | Chemiluminescence immunoassay | IgG|IgM | Structured |
| PMID:32711254 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375792/# | NaN | Singapore | SGP | Longitudinal | 156.0 | Chinese|Others | Clinical|Demographic|Laboratory | NaN | NaN | Age|Sex|Ethnicity | Plasma samples|Temperature |Heart rate| Respiratory rate | Diastolic blood pressure | Systolic blood pressure| Oxygen saturation | Haemoglobin|Haematocrit|Platelets|White blood cells|Lymphocytes|Neutrophils|Monocytes|C-reactive protein (CRP)|Creatinine|Lactate dehydrogenase| Alanine aminotransferase (ALT) | Diabetes|Hypertension|Others | NaN | NaN | IgG | Structured |
| PMID:32727884 | https://immunology.sciencemag.org/content/5/49/eabd5709 | NaN | USA | USA | Longitudinal | 1293.0 | Black/Non-Hispanic|White/Non-Hispanic|Hispanic/Latino|Asian|Other/Unknown | Laboratory|Demographic | NaN | NaN | Age |Sex | NaN | IgG|IgM | Obesity|Diabetes|Hypertension|Diabetes|Asthma | NaN | NaN | NaN | Structured |
Showing 1 to 10 of 50 entries
Geographic location of the studies
- 1:
- 2:
- 3:
- 4:
- 5:
- 6:
- 7:
- 10:
- 17: